Medtronic plc (MDT)

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story....

Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.